Docetaxel as a subsequent line after progression to platinum-based chemotherapy and immunotherapy.

Abstract

e21197 Background: Docetaxel was the standard of care for patients with non-small cell lung cancer (NSCLC) after platinum-based chemotherapy failure. The introduction of immune checkpoint inhibitors (ICIs) has radically altered the first-line treatment for advanced/metastatic NSCLC without driver mutations. However, limited clinical data are known after failure of chemotherapy and immunotherapy. Efficacy of docetaxel after progressing to platinum-based chemotherapy and checkpoint inhibitors are scarce. The aim of this study is to evaluate docetaxel in patients with advanced NSCLC after chemotherapy and ICIs failure in a real-world scenario. Methods: Retrospective, single centre study, including patients treated with docetaxel after progression to platinum-based chemotherapy and immunotherapy. We analysed demographic characteristics, treatments received and survival. Long survivors to Docetaxel were defined as those who lived more than 12 months after initiating Docetaxel. Results: 65 patients were included in this study. Median age was 67.0 years and 67.7% were male. 63.1% were adenocarcinoma, 24.6% squamous-cell carcinoma and 12.3% other histologies. Objective response rate (ORR) for docetaxel was 21.0%, with a control disease rate of 42.1%. 55.7% experienced toxicity from the treatment. Median progression-free survival (PFS) and overall survival (OS) were respectively 2.0 months (1.3-2.7, IQ 95%) and 6.0 months (4.6-7.4, IQ 95%). 16 patients (24.6%) were long survivors. Differential characteristics of long survivors are shown in Table. Conclusions: Docetaxel displayed poor survival results in our study after progression to platinum-based chemotherapy and ICIs, arising the necessity of developing new therapies for this scenario. Despite these results, almost 25% of the patients lived more than one year. Objective response to docetaxel was significantly associated with surviving more than one year, and better ECOG and lacking hepatic metastases showed a non-significant trend. Clinical biomarkers predicting benefit of Docetaxel in this scenario are lacking. [Table: see text]